Tag: Biotech and Pharmaceuticals
-
AstraZeneca shares drop 7% after report on $400 billion merger talks with Bristol Myers Squibb
The companies have discussed a potential merger over several months, the Financial Times reported on Sunday.
-
AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports
U.K. pharmaceutical giant AstraZeneca is considering a deal to merge with its U.S. rival Bristol Myers Squibb.
-
Novo Nordisk shares dive after heart medicine fails trial
The experimental medicine ziltivekimab didn’t translate into a statistically meaningful reduction in major cardiovascular adverse events, Novo said Friday.
-
New Medicaid work rules could cause patients to lose coverage, rare disease advocates warn
New Medicaid work requirements could put rare disease patients’ coverage at risk. NORD CEO Pamela Gavin explains how families can prepare.
-
Humana tops quarterly estimates, maintains profit outlook as medical costs stay in line
Humana maintained its 2026 adjusted profit outlook of at least $9 per share, which some analysts called a “disappointment” amid high expectations for insurers.
-
Why shareholders are suing Novo Nordisk over next-generation weight-loss drug
Investors claim Novo Nordisk misled the market about CagriSema’s tolerability, after disappointing clinical trial results wiped billions off its market cap.
-
Jim Cramer: J&J talc settlement is good for a stock that has so much going for it already
Jim Cramer described the recent trading action on Wall Street as a “J&J market.”
-
CDC says massive cyclospora outbreak is now in nine states
The four newly linked states – Illinois, Kansas, Oklahoma and Pennsylvania – join Indiana, Kentucky, Ohio, West Virginia and hard-hit Michigan.
-
Eli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trials
There are now positive results from five late-stage trials on retatrutide, which Lilly is positioning as the next pillar of its obesity portfolio.
-
Trump’s generic drug tariffs: What they could mean for medicine prices, manufacturers and supply
Trump’s generic drug tariff plan raises questions over prices, U.S. manufacturing and which drugmakers stand to gain or lose as details remain unclear.
Latest News
Stay Connected
Categories
BBC News CNA CNBC CNN International Deutsche Welle (DW) Euronews France 24 General Global & European Specialized & Regional
Tags
amp Artificial intelligence Asia Breaking News: Business Breaking News: Markets Breaking News: Politics Breaking News: Technology Business business news cent china cup Donald J. Trump Donald Trump economy European Union fast football France germany india Investment strategy iran Iran war markets People per politics return russia S&P 500 Index said Singapore spain Sport Stock markets technology trump ukraine United States US-Israel attack on Iran 2026 video War in Ukraine World World Cup 2026
About the Author
AF themes
Easy WordPress Websites Builder: Versatile Demos for Blogs, News, eCommerce and More – One-Click Import, No Coding! 1000+ Ready-made Templates for Stunning Newspaper, Magazine, Blog, and Publishing Websites.
Search the Archives
Access over the years of investigative journalism and breaking reports
You May Have Missed
